Biomedicines· 2026Q1· Review
Licochalcones in Pancreatic Ductal Adenocarcinoma and Type 2 Diabetes Mellitus: Context-Dependent Modulation of Shared Signaling Pathways and an Evidence-Stratified Framework
- 0citations
- Q1SCImago
- 2026year
Short summary
Licochalcones (LCs) show potential to simultaneously target shared signaling pathways in pancreatic cancer and type 2 diabetes, restoring insulin signaling and inhibiting oncogenic pathways.
AI-generated from the title and abstract; the full text is not read.
Key points
- PDAC and T2DM share common pathogenic mechanisms involving chronic inflammation, insulin resistance, metabolic reprogramming, and oxidative stress.
- Licochalcones (LCs) are natural compounds derived from licorice with potential to modulate these shared pathways.
- LCs may restore insulin signaling in metabolic tissues and inhibit oncogenic signaling in PDAC.
- Clinical studies on the comorbidity of PDAC and T2DM are insufficient, and the simultaneous antitumor and metabolic benefits of LCs are currently a hypothesis.
AI-generated from the title and abstract; the full text is not read.
Abstract
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) and type 2 diabetes mellitus (T2DM) share developmental links that are both driven by metabolic dysfunctions, complicating early diagnosis and treatment. This review systematically explores the shared pathogenic mechanisms and molecular pathways between PDAC and T2DM, including chronic inflammation (NF-κB/JNK/NLRP3), insulin resistance (PI3K/Akt), metabolic reprogramming (AMPK/mTOR), and oxidative stress (ROS/Nrf2). Methods: Licochalcones (LCs) are natural chalcone constituents derived from the roots of licorice (Glycyrrhiza Radix). The pharmacological activities of different subtypes of LCs (LCA-LCE) in the aforementioned common pathways have been comprehensively analyzed. Results: A possible bidirectional regulatory ability of LCs is proposed: it can restore insulin signaling in metabolically impaired tissues and inhibit abnormal oncogenic signaling pathways in PDAC. Although there are experimental bases, clinical studies on the comorbidity of PDAC and T2DM are still insufficient. This review evaluates whether the context-dependent effects of LCs reported in metabolic and tumor models provide a mechanistic basis for investigating PDAC–T2DM comorbidity. Conclusions: Direct PDAC findings are distinguished from metabolic evidence and non-PDAC tumor studies, while simultaneous antitumor and metabolic benefits remain a hypothesis requiring validation.
The authors' abstract, as published at the source. Biomedicines, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pharmacology (Pharmacology, Toxicology and Pharmaceutics)
PharmacologyPharmacology, Toxicology and Pharmaceutics